Clinical Trials in New York

Showing 2681-2700 of 22,668 trials

Long-term Safety and Efficacy of Leniolisib in PIDs With Immune Dysregulation

NCT06990529

This is an open-label extension (OLE) study to extend treatment to patients with primary immunodeficiency (PID) disorders linked to phosphoinositide 3-kinase delta signaling who participated in a prior study of leniolisib, LE 7201. The primary objective is to assess long-term safety and tolerability of leniolisib. Secondary and exploratory objectives include various efficacy and immunophenotyping measures for leniolisib.

PIDs Linked to PI3K

Pharming Technologies B.V.12 participantsStarted Apr 2025

Bethesda, Maryland, United States • Burlington, Massachusetts, United States • New York, New York, United States +1 more locations

COMPLETEDPhase 3< 1 mile

A Study of Aticaprant 10 Milligrams (mg) as Adjunctive Therapy in Adult Participants With MDD With Moderate-to-severe Anhedonia and Inadequate Response to Current Antidepressant Therapy

NCT05550532

The purpose of this study is to evaluate the efficacy of aticaprant compared with placebo as adjunctive therapy to an antidepressant in improving depressive symptoms in adult participants with major depressive disorder (MDD) with moderate to severe anhedonia (ANH+) who have had an inadequate response to current antidepressant therapy with a selective serotonin reuptake inhibitor (SSRI) or serotonin-norepinephrine reuptake inhibitor (SNRI).

Depressive Disorder, MajorAnhedonia

Janssen Research & Development, LLC444 participantsStarted Dec 2022

Birmingham, Alabama, United States • Lafayette, California, United States • Orange, California, United States +128 more locations

Long-term Safety and Efficacy of Leniolisib in PIDs With Immune Dysregulation

A Study of Aticaprant 10 Milligrams (mg) as Adjunctive Therapy in Adult Participants With MDD With Moderate-to-severe Anhedonia and Inadequate Response to Current Antidepressant Therapy

Find Trials by Condition in New York

A Study to Assess Disease Activity and Safety of Subcutaneous Lutikizumab (ABT-981) in Adult Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-Tumor Necrosis Factor (TNF) Therapy and Who Are Naïve to Biologic Therapy

Safety, Pharmacokinetics (PK), and Efficacy of ONC-783 in Advanced Solid Tumors

A Study of a Potential Disease Modifying Treatment in Individuals at Risk for or With a Type of Early Onset AD Caused by a Genetic Mutation

Clinical and Molecular Correlates of Positron Emission Tomography (PET) With 89Zr-DFO-huJ591 in Metastatic Prostate Cancer

Eliminating Monitor Overuse Trial (EMO Trial)

VK2735 for Weight Management Type 2 Diabetes Phase 3 (VANQUISH 2)

Assessment of the Efficacy and Safety of Olaparib Monotherapy Versus Physicians Choice Chemotherapy in the Treatment of Metastatic Breast Cancer Patients With Germline BRCA1/2 Mutations.

Comparing Patients' and Surgeons' Expectations of Lumbar Spine Surgery

A Study of CLSP-1025 in Adult Patients With Solid Tumors That Harbor the p53 R175H Mutation

Observational Study of LUMRYZ in Narcolepsy

A Study to Test if Fremanezumab is Effective in Preventing Migraine in Children and Adolescents

Clinical Study of Chondro-Gide® for Large Chondral Lesions in the Knee

Acceptance and Commitment Therapy to Improve Social Support for Veterans With PTSD

Dominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia. A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset Alzheimer's Disease Caused by a Genetic Mutation. Master Protocol DIAN-TU-001

Compassionate Use of Concizumab if You Have Haemophilia

Safety, Tolerability, PK, and PD Study of PGN-EDODM1 in Participants With Myotonic Dystrophy Type 1

5-SENSE Score Validation Study

Post Market Clinical Follow-up (PMCF) Study of the A.L.P.S. Proximal Humerus Plating System